Recent News
Jan 27, 2020

PharmaCielo will sell a broad range of extracts – including both CBD- and THC-dominant profiles – to XPhyto Therapeutics Corp., for German market distribution Three-year agreement signed,...

Jan 24, 2020

Company signs a three-year performance-based agreement with CBD Export Global Distribution channel covers the entire EU-zone as well as Switzerland and Lichtenstein Shipments to commence in 2020...

View more News

View Investor Presentation

If you have any questions please contact

CEO Letter to Shareholders
Q3 2019 Financial Information
Why Invest

We’re a dominant, vertically integrated Colombian cannabis company.

Colombia is one of the few global jurisdictions that have the readily scalable production capacity, expertise and legislative framework to sustainably meet global cannabis demand over the mid- and long-term. The country’s ideal growing environment and decades of experience has made it the foremost supplier of other agricultural commodities including coffee, cut flowers and bananas.

PharmaCielo’s management team and Board of Directors have experience scaling global commodity and consumer goods businesses both within Colombia and around the world. Learn more about our team here.

139 hectares (15 Million square feet) of available cultivation capacity1

PharmaCielo received its Colombian manufacturing licence in 2016 and has rapidly become the dominant player in Colombia’s rapidly growing legal cannabis sector. The company is licensed to produce both CBD-dominant and THC-dominant cannabis under quota from the Colombian government. The company was the first Colombian recipient of a licence to cultivate THC-dominant strains and produce THC-focused cannabis oil extracts.

PharmaCielo is on track to rapidly scale its vertically integrated Colombian operations, while expanding operations globally.

2019 commercial-scale production & sale

The company is currently producing CBD-focused cannabis oil extracts. PharmaCielo is completing the construction of its GMP2 certified (Good Manufacturing Practices) oil processing facility and expects to begin commercial-scale production and sale of both CBD-focused and THC-focused cannabis oil extracts during the second half of 2019.